Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Apros Therapeutics, Inc
APR003 is a small molecule TLR7 agonist that concentrates in the GI, and liver with limited systemic exposure. It is designed to increase the therapeutic window of a TLR7 agonist by minimizing the side-effects associated with generalized systemic immune activation and inflammation.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
ECOG performance status of 0 or 1
Must have disease that is considered non-surgically resectable.
Relapsed or persistent/refractory to at least two prior systemic treatment regimens for locally advanced or metastatic disease considered to be standard-of-care (SOC).
Must have previously received an irinotecan or oxaliplatin-based therapy, as well as a targeted antibody therapy for metastatic disease
Tumors that are MSI-H/dMMR must have previously received checkpoint inhibitor therapy
Adequate hepatic function
Adequate renal function
Normal coagulation panel
Willingness to use effective contraception
You may not be if
Current or history of CNS metastases
Significant cardiovascular disease
Pregnant or breastfeeding
Clareo Health | A Dose Escalation Study of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions
